Carmustine

CraniUS Appoints World Leading Neurosurgeon to Join Board of Directors

Retrieved on: 
Tuesday, November 15, 2022

BALTIMORE, Nov. 15, 2022 /PRNewswire/ -- CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain disease, announced today the appointment of Henry Brem, MD to its accomplished Board of Directors.

Key Points: 
  • Dr. Henry Brem joins CraniUS Board of Directors in further enhancing its mission to facilitate chronic and direct medicine delivery for treating brain disease.
  • Over the last several decades, Dr. Brem has built one of the largest and most prestigious brain tumor centers in the world.
  • With this, I cannot imagine a more ideal board member to help navigate CraniUS' path forward."
  • "I am absolutely thrilled to be joining the CraniUS Board of Directors.

Accord Healthcare Launches Generic Drug for Treating Brain Tumors & Blood Cancers

Retrieved on: 
Tuesday, August 23, 2022

DURHAM, N.C., Aug. 23, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Carmustine to its line of chemotherapy drugs. The drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Carmustine is therapeutically equivalent to Avet Pharmaceuticals Inc.'s BiCNUR and approved for use in the treatment of certain types of brain tumors and blood cancers. Accord is offering Carmustine in a 50-mg size, as well as the new, larger 300-mg strength, which was not previously available in the market and overcomes the potential need to use multiple vials of the smaller size.

Key Points: 
  • DURHAM, N.C., Aug. 23, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Carmustine to its line of chemotherapy drugs.
  • "Adding this chemotherapy drug to our portfolio illustrates Accord's commitment in the US market to support healthcare providers in prescribing accessible oncology medications."
  • Further information about safety and potential side effects can be found on the Products page at Accord Healthcare US.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.

Implantable Drug Delivery Devices Global Market Report 2022-2026: Rise in the Incidence of Target Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022

The "Implantable Drug Delivery Devices Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Implantable Drug Delivery Devices Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market.
  • Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market.
  • Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market.

Global Brain Tumor Drugs Market (2022 to 2031) - Featuring Pfizer, Shimadzu and Celgene Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 7, 2022

The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.

Key Points: 
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib.
  • The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide.
  • Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market.

Drug Delivery in Cancer Technologies, Markets & Competitive Landscape, 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021

The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • Cancer market estimates from 2020-2030 are given according to organs involved and the types of cancer as well as according to technologies.
  • These may be injected into the arterial circulation and guided to the tumor by a magnetic field for targeted drug delivery.
  • Cancer gene therapy is a sophisticated form of drug delivery for cancer.

Implantable Drug Delivery Devices Global Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 12, 2021

The "Implantable Drug Delivery Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Implantable Drug Delivery Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The implantable drug delivery devices market consists of sales of implantable drug delivery devices and related services by companies that manufacture them.
  • Implantable drug delivery devices are drug delivery systems implanted by surgery to allow site-specific drug administration at the tissue or organ where the drug is most needed.
  • Hence, due to the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market.

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

Retrieved on: 
Friday, September 18, 2020

Brain metastasis is a significant concern in patients with TNBC, and we are very encouraged by these early-stage study results, stated Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.

Key Points: 
  • Brain metastasis is a significant concern in patients with TNBC, and we are very encouraged by these early-stage study results, stated Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.
  • European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
  • Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
  • Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

STI Pharma Announces US Launch of Generic BICNU® for Injection

Retrieved on: 
Thursday, November 21, 2019

NEWTOWN, Pa., Nov. 21, 2019 /PRNewswire/ -- STI Pharma, LLC today announced the US launch of Carmustine for Injection, USP: 1 Kit (100mg per Vial & Diluent), a generic version of AVET's (formerly Heritage) BiCNU.

Key Points: 
  • NEWTOWN, Pa., Nov. 21, 2019 /PRNewswire/ -- STI Pharma, LLC today announced the US launch of Carmustine for Injection, USP: 1 Kit (100mg per Vial & Diluent), a generic version of AVET's (formerly Heritage) BiCNU.
  • STI received the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.
  • "The launch of Carmustine Injection is an important milestone for STI, representing our first oncology injectable approval," said STI President Frank Mullery.
  • STI Pharma, located in Newtown, PA, was founded in 2008 by a team of industry veterans.

Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch

Retrieved on: 
Friday, October 19, 2018

BRIDGEWATER, N.J., Oct. 19, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU (carmustine) for injection, 100 mg.

Key Points: 
  • BRIDGEWATER, N.J., Oct. 19, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU (carmustine) for injection, 100 mg.
  • "It has been a very productive year for Amneal as our generic pipeline continues to deliver new opportunities," said Rob Stewart, President and CEO of Amneal.
  • "Year to date, we have received FDA approval on 48 ANDA's, tentative approval on another 10 ANDA's and have launched 30 products."
  • According to IQVIA, U.S. market annual sales for the 12 months ended August 2018 for Carmustine for Injection USP, 100 mg/vial is estimated to be approximately $84 million.